EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma

Jelena Jelicic iD, Karen Juul-Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown iD, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jelena Jelicic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, beta 2-Microglobulin, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several clinical prognostic models for diffuse large B‐cell lymphoma (DLBCL) have been proposed, including the most commonly used International Prognostic Index (IPI), the National Comprehensive Cancer Network IPI (NCCN‐IPI), and models incorporating beta‐2 microglobulin (β2M). However, the role of β2M in DLBCL patients is not fully understood.

Methods

We identified 6075 patients with newly diagnosed DLBCL treated with immunochemotherapy registered in the Danish Lymphoma Registry.

Results

A total of 3232 patients had data available to calculate risk scores from each of the nine considered risk models for DLBCL, including a model developed from our population. Three of four models with β2M and NCCN‐IPI performed better than the International Prognostic Indexes (IPI, age‐adjusted IPI, and revised IPI). Five‐year overall survival for high‐ and low‐risk patients were 43.6% and 86.4% for IPI and 34.9% and 96.2% for NCCN‐IPI. In univariate analysis, higher levels of β2M were associated with inferior survival, higher tumor burden (advanced clinical stage and bulky disease), previous malignancy and increased age, and creatinine levels. Furthermore, we developed a model (β2M‐NCCN‐IPI) by adding β2M to NCCN‐IPI (c‐index 0.708) with improved discriminatory ability compared to NCCN‐IPI (c‐index 0.698, p < 0.05) and 5‐year OS of 33.1%, 56.2%, 82.4%, and 96.4% in the high, high‐intermediate, low‐intermediate and low‐risk group, respectively.

Conclusion

International Prognostic Indices, except for NCCN‐IPI, fail to accurately discriminate risk groups in the rituximab era. β2M, a readily available marker, could improve the discriminatory performance of NCCN‐IPI and should be re‐evaluated in the development setting of future models for DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, Diffusebeta 2-MicroglobulinBiomarkers, TumorHumansMaleFemalePrognosisMiddle AgedAgedAdultAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsYoung AdultDenmarkAdolescentNeoplasm StagingRegistries

Stichwörter der Autor:innen

non‐Hodgkin lymphomaprognosisprognostic factorsrisk model

Substanzen

beta 2-MicroglobulinBiomarkers, TumorB2M protein, human

Autor:innen und Institutionen

  • Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Faculty of Medicine, Institute for Medical Statistics and Informatics, University of Belgrade, Belgrade, Serbia.
  • Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Hematology, Vejle Hospital, Sygehus Lillebaelt, Vejle, Denmark.
  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Hematology, Regional Hospital Gødstrup, Herning, Denmark.

ORCID-Profile: Jelena Jelicic, Peter Brown, Thomas Stauffer Larsen

Zitieren

APA

Jelicic, J., Juul-Jensen, K., Bukumiric, Z., Runason Simonsen, M., Roost Clausen, M., Ludvigsen Al-Mashhadi, A., Schou Pedersen, R., Bjørn Poulsen, C., Ortved Gang, A., Brown, P., El-Galaly, T. C., & Larsen, T. S. (2024). Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma. Cancer Medicine. https://doi.org/10.1002/cam4.7239

Vancouver

Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, et al. Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma. Cancer Medicine. 2024. doi:10.1002/cam4.7239

BibTeX
@article{Jelicic2024,
  author = {Jelicic, Jelena and Juul-Jensen, Karen and Bukumiric, Zoran and Runason Simonsen, Mikkel and Roost Clausen, Michael and Ludvigsen Al-Mashhadi, Ahmed and Schou Pedersen, Robert and Bjørn Poulsen, Christian and Ortved Gang, Anne and Brown, Peter and El-Galaly, Tarec Christoffer and Larsen, Thomas Stauffer},
  title = {Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7239}
}
Kostenlos starten →